Dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders
GBT (NASDAQ: GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT’s lead product candidate is voxelotor (formerly known as GBT440), an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which the company believes inhibits hemoglobin polymerization in sickle cell disease.
Year Invested: 2012
Location: South San Francisco, Calif.
Visit: www.gbt.com/
Recent News
June 15, 2018
GBT Announces New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease (SCD) at 23rd European Hematology Association (EHA) Congress
June 8, 2018
GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease (SCD) Program at Foundation for Sickle Cell Disease Research’s 12th Annual Symposium
June 5, 2018
GBT Announces New Employment Inducement Grants
Read More News
Associated Team Members
Kevin Starr
Partner
Craig Muir
Partner/Chief Technology Officer
Charles Homcy, M.D.
Partner
Glenn Pierce, M.D., Ph.D.
Entrepreneur-in-Residence